Search Results

As geopolitical tensions between the U.S. and China grow increasingly complicated, here are five alternative territories for biotech investments.

Agreement targets commercialization through the physical retail network of Nahdi Medical Company, Saudi Arabia’s largest pharmacy chain. Highlights Five-year definitive agreement with approximately US$3.8 million in potential minimum purchase commitments, beginning with a firm 10,000-unit initial purchase order. Agreement covers a private-label version of VIVI Cap™ intended for retail commercialization through the physical pharmacy network of Nahdi Medical Company, Saudi Arabia’s largest pharmacy chain. TempraMed believes the private-label structure can improve in-store commitment, pharmacist engagement and consumer promotion as the product is expected to be positioned as part of Nahdi’s own retail offering. Commercial launch is subject to applicable Saudi regulatory clearance, after which 60% of the initial purchase price becomes payable by bank transfer, with the remaining balance secured through a Letter of Credit